ReviewCancer biology & medicine2015
Advances in immunotherapy for treatment of lung cancer.
Review in Cancer biology & medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Harnessing miR-145 in NSCLC: mechanistic roles, diagnostic-prognostic utility, and therapeutic potential.Cancer cell international · 2025Review
- Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [Quantitative imaging in medicine and surgery · 2022Article
- Article
- Role of immunotherapy in oligometastatic nonsmall cell lung cancer.BMJ case reports · 2021Article
- The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.International journal of biological sciences · 2021Article
- LncRNA SNHG10 is downregulated in non-small cell lung cancer and predicts poor survival.BMC pulmonary medicine · 2020Article
- Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.Cancer biology & medicine · 2020Review
- Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab.Cancer biology & medicine · 2020Article
- Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?International journal of molecular sciences · 2018Review
- Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation.Scientific reports · 2018Article
- New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.OncoTargets and therapy · 2018Review
- The paradoxical role of tumor-infiltrating immune cells in lung cancer.Intractable & rare diseases research · 2017Review
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Therapeutic advances in respiratory disease · 2017Review
- Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Oncotarget · 2017Review
- Article
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?Oman medical journal · 2017Article
- Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.Frontiers in immunology · 2017Article
- The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.Ochsner journal · 2017Review
- Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Frontiers in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different approaches for treating lung cancer have been developed over time, including chemotherapy, radiotherapy and targeted therapies against activating mutations. Lately, better understanding of the role of the immunological system in tumor control has opened multiple doors to implement different strategies to enhance immune response against cancer cells. It is known that tumor cells elude immune response by several mechanisms. The development of monoclonal antibodies against the checkpoint inhibitor programmed cell death protein 1 (PD-1) and its ligand (PD-L1), on T cells, has led to high activity in cancer patients with long lasting responses. Nivolumab, an anti PD-1 inhibitor, has been recently approved for the treatment of squamous cell lung cancer patients, given the survival advantage demonstrated in a phase III trial. Pembrolizumab, another anti PD-1 antibody, has received FDA breakthrough therapy designation for treatment of non-small cell lung cancer (NSCLC), supported by data from a phase I trial. Clinical trials with anti PD-1/PD-L1 antibodies in NSCLC have demonstrated very good tolerability and activity, with response rates around 20% and a median duration of response of 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.